Summary

for people ages 18 years and up (full criteria)
healthy people welcome
at UC Davis
study started
estimated completion:
Richard Applegate (ucdavis)

Description

Summary

This study is a comparison of the analgesic efficacy of transversus abdominis plane (TAP) blocks with ropivacaine bolus plus continuous ropivacaine infusion via catheters versus single shot TAP blocks with liposomal bupivacaine.

Official Title

Transversus Abdominis Plane (TAP) Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine: A Prospective Randomized Control Trial for Pain Control After Renal Transplant Surgery

Details

This study is a comparison of the analgesic efficacy of TAP blocks provided by ropivacaine bolus plus continuous ropivacaine infusion via catheters versus single shot TAP blocks with liposomal bupivacaine.

In the Liposomal Bupivacaine group, TAP block will be performed using ultrasound guidance. 12ml of 0,25% plain bupivacaine will be used for skin infiltration and to open up the TAP. Liposomal Bupivacaine 266 mg (1.3% in 20 ml) will be diluted to 40 ml volume with 20 ml of preservative free normal saline. 20 ml (133mg) of liposomal bupivicaine will then be injected into the TAP.

For those randomized to the TAP catheter group, ultrasound guidance will be used for TAP block and 5 mls 1% lidocaine will be used for skin infiltration. A peripheral nerve catheter will be placed approximately 3-5 cm into the TAP space after injection of ropivacaine. A bolus dose of 2.5 mg/kg of ropivacaine will be administered in a volume of 30 ml up to a maximum of 150 mg. An infusion with a programmable pump will be initiated at a rate of 8 ml/hr of 0.2% ropivacaine on the inpatient floor.

Keywords

Transplant;Failure,Kidney Pain, Postoperative Transversus Abdominis Plane Block Ropivacaine Liposomal bupivacaine Renal Insufficiency Bupivacaine Ropivacaine Continuous Infusion Catheter Single Dose Liposomal Bupivicaine

Eligibility

You can join if…

Open to people ages 18 years and up

  • Patients ages 18 years or older
  • Renal Transplant Recipients

You CAN'T join if...

  • Patients less than 18 years of age
  • Pregnant Women
  • Prisoners
  • Opioid Tolerant Patients taking more than 30 mg/day of oral morphine equivalent analgesia
  • Patients on Systemic anti coagulation
  • Patients unable to provide consent
  • Hypersensitivity to amide-type local anesthetic or any component of the drug formula

Location

  • University of California Davis accepting new patients
    Sacramento California 95817 United States

Lead Scientist

  • Richard Applegate (ucdavis)
    Prof/Chair, Anesthesiology and Pain Medicine. Authored (or co-authored) 52 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, Davis
ID
NCT03737604
Phase
Phase 4
Study Type
Interventional
Last Updated